NPHCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

NUTRA PHARMA CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $806.69K
P/E (TTM): –
Dividend yield: –

NUTRA PHARMA CORP income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	0.26	0.25	0.21	0.15	0.10	0.05	0.10	0.13	0.12	0.17	0.29	0.59	0.10	0.20	0.16	1.43	–
Cost of Revenue	0.18	0.24	0.18	0.16	0.04	–	–	0.07	0.03	0.04	0.07	0.11	0.04	0.15	0.88	0.62	–
Gross Profit	0.20	0.25	0.40	0.25	0.01	0.01	0.03	0.01	0.09	-0.05	0.23	0.48	0.06	0.06	-0.72	0.82	–
Research & Development	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.09	0.19	–
Selling, General & Admin	–	1.13	1.18	2.08	1.93	1.10	1.20	1.39	1.48	1.99	5.99	2.68	2.43	2.66	3.04	3.95	–
Advertising Expenses	–	–	–	–	–	–	–	–	0.00	0.00	0.00	–	0.00	0.07	0.10	–	–
Operating Expenses	1.66	1.13	1.28	2.16	2.00	0.94	1.26	1.89	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	0.12	0.12	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-1.46	-0.88	-0.89	-1.91	-1.99	-0.92	-1.23	-1.88	-1.38	-2.04	-5.77	-2.20	-2.36	-2.60	-3.95	-3.40	–
Interest Expense	0.02	0.02	0.02	0.02	0.02	0.32	0.24	0.57	0.34	0.29	0.43	0.13	0.16	0.15	0.42	0.07	–
Other Non-Operating Income	-0.59	-0.41	-0.51	10	-11	0.16	-5.36	-2.01	–	–	0.37	-0.33	-1.98	-1.01	-0.45	0.33	–
Gain (Loss) on Sale of Assets	–	–	0.04	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	0.20	–	–	–	1.03	0.01	0.04	–	–	–	–
Pretax Income	-2.05	-1.29	-1.39	8.18	-13	-0.77	-6.59	-3.88	-4.03	-3.45	-5.39	-2.53	-4.34	-3.61	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	0	0	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	-4.03	-3.45	-5.39	-2.53	–	–	–	–	–
Net Income	-2.05	-1.29	-1.39	8.18	-13	-0.77	-6.59	-3.88	-4.03	-3.45	-5.39	-2.53	-4.34	-3.61	-4.40	-3.06	-2.30
EPS (Basic)(per share)	0.00	0.00	0.00	0.00	-0.0018	0.00	0.00	0.00	0.00	-0.02	-0.10	-0.08	-0.40	-0.40	-0.40	-0.40	–
EPS (Diluted)(per share)	0.00	0.00	0.00	0.00	-0.0018	0.00	0.00	0.00	0.00	-0.02	-0.10	-0.08	-0.40	-0.40	-0.40	-0.40	–
Shares Outstanding (Basic, Weighted)(shares)	7,779	7,674	7,608	7,503	7,233	6,607	4,710	3,187	1,048	168	56	31	19	10	7.44	–	–
Shares Outstanding (Diluted, Weighted)(shares)	7,779	7,674	7,608	19,097	7,233	6,607	4,710	3,187	1,048	168	56	31	19	10	7.44	–	–
EBITDA	–	–	–	–	-1.98	-0.92	–	–	-1.38	-2.03	-5.75	-2.19	-2.35	-2.59	-3.93	-3.38	–
Net Interest Income	–	–	–	–	–	–	–	0.01	–	–	–	–	–	–	–	–	–
Provision for Credit Losses	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0.10	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.8%
Operating margin: -1017.8%
Net margin: -3370.6%
Return on equity, FY2025: 12.9%

Financial strength

Current ratio: 0.02
Debt to equity: -0.59
Debt to assets: 2018.7%
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 5.02
Price to book: –
Dividend yield: –